Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Wan Ling Tan, Kevin L.M. Chua, Chia Chi Lin, Victor H.F. Lee, Lye Mun Tho, Anthony W. Chan, Gwo Fuang Ho, Thanyanan Reungwetwattana, James C. Yang, Dong Wan Kim, Ross A. Soo, Yong Chan Ahn, Hiroshi Onishi, Myung Ju Ahn, Tony S.K. Mok, Daniel S.W. Tan, Fan Yang

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a clinical challenge. Recent changes in the American Joint Commission on Cancer staging to the eighth edition has led to a shift in TNM stage grouping and redefined the subcategories (IIIA–C) in stage III NSCLC for better prognostication. Although concurrent chemoradiotherapy has remained standard-of-care for stage III NSCLC for almost 2 decades, contemporary considerations include the impact of different molecular subsets of NSCLC, and the roles of tyrosine kinase inhibitors post-definitive therapy and of immune checkpoint inhibitors following chemoradiotherapy. With rapid evolution of diagnostic algorithms and expanding treatment options, the need for interdisciplinary input involving multiple specialists (medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists and thoracic surgeons) has become increasingly important. The unique demographics of Asian NSCLC pose further challenges when applying clinical trial data into clinical practice. This includes differences in smoking rates, prevalence of oncogenic driver mutations, and access to health care resources including molecular testing, prompting the need for critical review of existing data and identification of current gaps. In this expert consensus statement by the Asian Thoracic Oncology Research Group, an interdisciplinary group of experts representing Hong Kong, Korea, Japan, Taiwan, Singapore, Thailand, Malaysia, and Mainland China was convened. Standard clinical practices for stage III NSCLC across different Asian countries were discussed from initial diagnosis and staging through to multi-modality approaches including surgery, chemotherapy, radiation, targeted therapies, and immunotherapy.

Original languageEnglish
Pages (from-to)324-343
Number of pages20
JournalJournal of Thoracic Oncology
Volume15
Issue number3
DOIs
StatePublished - Mar 2020

Keywords

  • Asian
  • Consensus statement
  • Stage III NSCLC

Fingerprint Dive into the research topics of 'Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC'. Together they form a unique fingerprint.

  • Cite this

    Tan, W. L., Chua, K. L. M., Lin, C. C., Lee, V. H. F., Tho, L. M., Chan, A. W., Ho, G. F., Reungwetwattana, T., Yang, J. C., Kim, D. W., Soo, R. A., Ahn, Y. C., Onishi, H., Ahn, M. J., Mok, T. S. K., Tan, D. S. W., & Yang, F. (2020). Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. Journal of Thoracic Oncology, 15(3), 324-343. https://doi.org/10.1016/j.jtho.2019.10.022